Combination cyclin-dependent kinase 4/6 inhibitors and endocrine ...
Meta-analysis shows CDK 4/6 inhibitors plus ET improve PFS and OS in HR+/HER2- ABC, despite higher grade 3/4 AEs risk, outperforming ET alone across treatment lines and menopausal statuses.
Reference News
Combination cyclin-dependent kinase 4/6 inhibitors and endocrine ...
Meta-analysis shows CDK 4/6 inhibitors plus ET improve PFS and OS in HR+/HER2- ABC, despite higher grade 3/4 AEs risk, outperforming ET alone across treatment lines and menopausal statuses.